1. Home
  2. BTBD vs SNGX Comparison

BTBD vs SNGX Comparison

Compare BTBD & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BT Brands Inc.

BTBD

BT Brands Inc.

HOLD

Current Price

$1.28

Market Cap

7.1M

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.40

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTBD
SNGX
Founded
1987
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
5.6M
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
BTBD
SNGX
Price
$1.28
$0.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
36.9K
210.9K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
$14,823,472.00
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.31
N/A
52 Week Low
$1.03
$0.28
52 Week High
$4.50
$6.23

Technical Indicators

Market Signals
Indicator
BTBD
SNGX
Relative Strength Index (RSI) 62.43 53.16
Support Level $1.20 $0.37
Resistance Level $1.67 $0.41
Average True Range (ATR) 0.07 0.02
MACD 0.01 0.01
Stochastic Oscillator 92.31 87.85

Price Performance

Historical Comparison
BTBD
SNGX

About BTBD BT Brands Inc.

BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: